Skip to main content

Table 2 CMR measurements

From: Scar heterogeneity on cardiovascular magnetic resonance as a predictor of appropriate implantable cardioverter defibrillator therapy

 

Appropriate ICD therapy

No appropriate ICD therapy

P-value*

 

n = 7

n = 33

 

LVM (g)

173 ± 30

160 ± 47

0.599

LVMI (g/m2)

91 ± 14

82 ± 20

0.369

LVEF (%)

23 ± 6.5

31 ± 9

0.04

LVEDV (ml)

263 ± 34

268 ± 107

0.831

LVEDVI (ml/m2)

140 ± 29

137 ± 45

0.559

LVESV (ml)

202 ± 35

195 ± 93

0.546

RVEDV (ml)

128 ± 19

160 ± 71

0.369

RVEDVI (ml/m2)

69 ± 12

78 ± 20

0.443

RVESV (ml)

66 ± 5.5

77 ± 41

0.719

RVEF (%)

48 ± 8

51 ± 12

0.332

LGE presence (%)

6 (86)

19 (57)

0.155

LGE4SD (g)

44 ± 29

27 ± 31

0.112

LGE6SD (g)

32 ± 25

21 ± 27

0.193

Visual (g)

34 ± 23

24 ± 28

0.245

HSA2-4SD (g)

17 ± 12

5 ± 7

0.001

HSA4-6SD (g)

11 ± 10

5 ± 7

0.038

  1. LVM:Left ventricular mass; LVMI:left ventricular mass index; LVEDV:left ventricular end-diastolic volume; LVEDVI:left ventricular end-diastolic volume index; LVESV:left ventricular end-systolic volume; RVEDV:right ventricular end-diastolic volume; RVEDVI:right ventricular end-diastolic volume index; RVESV:left ventricular end-systolic volume; RVEF:right ventricular ejection fraction; LGE: late gadolinium enhancement; HSA:heterogenous scar area.
  2. * Univariate Cox’s proportional hazard model.
  3. # HSA2-4SD and HSA4-6SD were highly correlated (r=0.69, p-value: 0.0001), so only HSA2-4SD was entered into the multivariate model.
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us